Translational Kidney Cancer Research Programme: Current Work and Five-Year Vision

“Our vision is to transform early kidney cancer care by combining immune biology, advanced         analytics, and surgical innovation to deliver more precise, personalised treatment for patients.”

Research to Date

The Meena Raja Kidney Cancer Foundation supports a translational research programme focused on the immunobiology of kidney cancer and innovation in surgical care. Embedded within the Specialist Centre for Kidney Cancer (SCKC) at the Royal Free Hospital and working closely with the UCL Institute of Immunology and Transplantation, the programme operates within one of Europe’s highest-volume kidney cancer services. Research to date has focused on longitudinal immune profiling before and after kidney cancer interventions, including surgery and ablation, examining immune dynamics in relation to tumour behaviour and treatment response. Foundation funding has supported PhD-level research, a dedicated clinical kidney cancer database, and specialist research and robotic surgery fellowships. Five-Year Research Plan

The programme aims to establish an integrated immune–clinical framework for early kidney cancer:

• Longitudinal immune profiling across diQerent management pathways (surgery and ablation)
• Bringing together immune and genomic data with clinical, imaging, and pathology information to better understand tumour behaviour
• Identification of immune signatures associated with tumour progression, treatment response, and clinical outcomes

Translational and Clinical Impact

The ultimate goal of this programme is to deliver clinically meaningful advances, including: 

• Improved risk stratification to guide surveillance versus early intervention
• Better identification of patients most likely to benefit from immune-based therapies
• Improved surgical precision and reduced variation through robotic and digitally supported surgery

Infrastructure and Equipment Requirements

• Advanced immune profiling platforms, including high-throughput sequencing
• Dedicated bioinformatics and secure computational infrastructure for longitudinal analysis
• Next-generation robotic and ultra-low-latency tele-surgical technologies

These capital investments, typically ranging from tens to several hundreds of thousands of pounds, are essential to enable high-resolution analysis and accelerate translation into clinical practice. Five-Year Vision

Within five years, the Meena Raja Kidney Cancer Foundation aims to support a fully integrated translational ecosystem in kidney cancer, combining immune biology, advanced analytics, and surgical innovation. This will position the programme as a national and international leader in early kidney cancer research, translating discovery into tailored treatments, improved surgical care, and ultimately helping patients access greater choice and better outcomes.